rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.
|
31566309 |
2019 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
|
30963570 |
2019 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we investigate molecular responses upon single and multi-target treatments, over time, using BRAF(V600E) mutant colorectal cancer cells as a model system.
|
29970458 |
2018 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.
|
30463788 |
2018 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.
|
27354468 |
2017 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Concomitant with such properties, EBI-907 exhibits potent and selective cytotoxicity against a broader range of BRAF(V600E)-dependent cell lines including certain colorectal cancer cell lines with innate resistance to Vemurafenib.
|
26810733 |
2016 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAF(V600E) mutation.
|
26208524 |
2015 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of the BRAF V600E mutation in colorectal cancer by immunohistochemistry is a viable alternative to molecular methods.
|
23650027 |
2013 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in colorectal cancer.
|
21516079 |
2011 |
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Real-time polymerase chain reaction identifies the most common BRAF mutation, V600E, in frozen or paraffin-embedded colorectal cancer tissue.
|
20670148 |
2010 |